Continuous Glucose Monitors to Regulate Glucose Levels in Type 2 Diabetics - (Protocol 3)

NCT ID: NCT03290768

Last Updated: 2021-05-18

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

358 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-09-13

Study Completion Date

2018-06-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study allows Type 2 diabetics to receive feedback from a continuous glucose monitor (CGM) as part of an educational program designed to help them better manage their glucose levels. Subjects will also wear an activity tracker to monitor their activity and observe its effect on their glucose levels. The educational program will involve calls from coaches to check subjects' progress and answer questions.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type2 Diabetes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Diabetes Management Educational Program

Subjects receive a CGM and activity tracker as part of a educational program to help manage their glucose levels.

Group Type EXPERIMENTAL

Continuous Glucose Monitor (CGM)

Intervention Type DEVICE

Subjects will use a CGM to develop an understanding of how their behaviors influence their glucose levels.

Activity Tracker

Intervention Type DEVICE

Subjects will use the activity tracker, in combination with a continuous glucose monitor (CGM), to develop an understanding of how their activity levels affect their glucose levels.

Coaching

Intervention Type BEHAVIORAL

Coaches will help subjects understand the readings from the CGMs and how they are affected by diet choices, use of diabetes medications, etc. Coaches and subjects will have weekly conversations about CGM data and behaviors that affect CGM readings. Coaching will occur via telephone, text messaging, and automated text messaging.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Continuous Glucose Monitor (CGM)

Subjects will use a CGM to develop an understanding of how their behaviors influence their glucose levels.

Intervention Type DEVICE

Activity Tracker

Subjects will use the activity tracker, in combination with a continuous glucose monitor (CGM), to develop an understanding of how their activity levels affect their glucose levels.

Intervention Type DEVICE

Coaching

Coaches will help subjects understand the readings from the CGMs and how they are affected by diet choices, use of diabetes medications, etc. Coaches and subjects will have weekly conversations about CGM data and behaviors that affect CGM readings. Coaching will occur via telephone, text messaging, and automated text messaging.

Intervention Type BEHAVIORAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Dexcom Investigational Use Only (IUO) Device Fitbit Charge 2

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Be diagnosed with type 2 diabetes
* Be able to read and understand English
* Have access to a telephone
* Have a Medicare Advantage health plan through Senior Dimensions

Exclusion Criteria

* Pregnant
* Blind
* Deaf
* Receiving chemotherapy or radiation to treat cancer (now or in past 6 months)
* Misusing any drugs (including alcohol, painkillers, hallucinogens, or others)
* Critically ill
* Diagnosed with or experiencing:

* Kidney disease stages 4 and 5
* End stage renal disease
* Severe liver disease
* Dementia
* Schizophrenia
* Bipolar disorder
* Autism
* An intellectual or learning disability
* Arrhythmias other than atrial fibrillation
* Congestive heart failure
* Has had a:

* Myocardial infarction within the last 6 months
* Stroke within the last 6 months
* Stroke that resulted in significant disability (e.g., unable to write clearly or walk)
Minimum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Savvysherpa, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Southwest Medical Associates

Las Vegas, Nevada, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Pro00022589

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Examining The Role of CGM in T2DM
NCT01614262 COMPLETED NA
Dexcom G6 Intervention Study
NCT03877068 COMPLETED NA
CGM Use in Non-insulin Patients With DM2
NCT07128342 NOT_YET_RECRUITING NA